scholarly article | Q13442814 |
P50 | author | Janet Pope | Q48742471 |
Marco Matucci-Cerinic | Q19859583 | ||
P2093 | author name string | Yannick Allanore | |
Weng Kee Wong | |||
Maureen D Mayes | |||
Athol U Wells | |||
Christopher P Denton | |||
Dinesh Khanna | |||
James R Seibold | |||
Kristine Phillips | |||
Oliver Distler | |||
Peter A Merkel | |||
Susanna M Proudman | |||
Murray Baron | |||
Janet E Pope | |||
Shervin Assassi | |||
Robert W Simms | |||
Virginia Steen | |||
Daniel E Furst | |||
Philip J Clements | |||
Edward H Giannini | |||
Elena Schiopu | |||
Sindhu R Johnson | |||
Veronica J Berrocal | |||
Jeffrey Siegel | |||
P2860 | cites work | Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial | Q46623011 |
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | Q47643186 | ||
Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey | Q48327217 | ||
Clinical trial design in scleroderma: where are we and where do we go next? | Q48562434 | ||
A note on a general definition of the coefficient of determination | Q56505617 | ||
Strictly Proper Scoring Rules, Prediction, and Estimation | Q56553210 | ||
Measurement of patient outcome in arthritis | Q56879288 | ||
Development of classification and response criteria for rheumatic diseases | Q57244852 | ||
Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group | Q67285449 | ||
Responsiveness to change: an aspect of validity, not a separate dimension | Q67481757 | ||
A disease severity scale for systemic sclerosis: development and testing | Q73101147 | ||
Severe organ involvement in systemic sclerosis with diffuse scleroderma | Q73202420 | ||
A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma | Q74024124 | ||
BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000 | Q80370140 | ||
What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG) | Q84583792 | ||
Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies | Q26864958 | ||
Mortality in systemic sclerosis: an international meta-analysis of individual patient data | Q30980001 | ||
Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score | Q33563148 | ||
Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis | Q33567430 | ||
ATS Statement | Q34136219 | ||
Assessment of kidney involvement. | Q34218311 | ||
Definitions and diagnosis of pulmonary hypertension. | Q34393150 | ||
Cyclophosphamide versus placebo in scleroderma lung disease. | Q34540647 | ||
Concepts of functioning and health important to people with systemic sclerosis: a qualitative study in four European countries. | Q34905661 | ||
Methods of formal consensus in classification/diagnostic criteria and guideline development | Q35091202 | ||
Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. | Q35176779 | ||
Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis | Q35878701 | ||
Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis | Q35977294 | ||
Old medications and new targeted therapies in systemic sclerosis | Q36154430 | ||
Scleroderma: from cell and molecular mechanisms to disease models | Q36259889 | ||
Systemic sclerosis - continuing progress in developing clinical measures of response. | Q36810200 | ||
Outcome measures in systemic sclerosis: an update on instruments and current research | Q36821503 | ||
A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease | Q36944847 | ||
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. | Q37013037 | ||
Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials | Q37301159 | ||
Quality indicator set for systemic sclerosis. | Q37460639 | ||
Development of a provisional core set of response measures for clinical trials of systemic sclerosis | Q37460792 | ||
Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial | Q37460808 | ||
Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). | Q37612672 | ||
The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment | Q37940672 | ||
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. | Q39632069 | ||
Disease and symptom burden in systemic sclerosis: a patient perspective. | Q40197495 | ||
European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score | Q43050321 | ||
Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. | Q44441787 | ||
P433 | issue | 2 | |
P304 | page(s) | 167-178 | |
P577 | publication date | 2016-02-01 | |
P1433 | published in | Arthritis Care and Research | Q15754720 |
P1476 | title | The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis | |
P478 | volume | 68 |